DGAP-Adhoc: QIAGEN N.V.: QIAGEN N.V. revises full-year 2014 adjusted EPS guidance and reaffirms fourth-quarter and full-year 2014 adjusted net sales guidance / announces offer to repurchase existing 2024 convertible notes

QIAGEN N.V.  / Key word(s): Preliminary Results/Capital Reorganisation

11.01.2015 18:20

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc Announcement according to § 15 WpHG

QIAGEN N.V. revises full-year 2014 adjusted EPS guidance and reaffirms
fourth-quarter and full-year 2014 adjusted net sales guidance

QIAGEN N.V. announces offer to repurchase existing 2024 convertible notes

The Managing Board of QIAGEN N.V. today resolved to take pre-tax charges to
its results for 2014, of approximately $47 million (or approximately $0.14
of adjusted diluted earnings per share), and of which $38 million involve
non-cash items.

Following the acquisition of Enzymatics, Inc., which was completed in
December 2014, QIAGEN has decided to take a business integration and
acquisition-related pre-tax charge on operating income in the fourth
quarter of 2014 of approximately $21 million (or approximately $0.06 per
share), and of which $18 million are non-cash items. These charges, which
will be excluded from adjusted results, involve actions to reduce
overlapping activities and sites, including the closing of the
Gaithersburg, Maryland, site. In addition, following a review to further
improve efficiency and effectiveness, QIAGEN will now take a pre-tax charge
on operating income for restructuring measures in the fourth quarter of
2014 of approximately $26 million (or approximately $0.08 per share), and
of which $20 million are non-cash items. In line with QIAGEN's policy,
these restructuring charges, which primarily involve impairments of
technology-related assets, will not be excluded from adjusted results.

For full-year 2014, QIAGEN expects to achieve its previously announced
guidance for adjusted diluted EPS of $1.08 CER (constant exchange rates),
but for these results to be reduced to approximately $1.00 CER as a result
of the restructuring charges.

QIAGEN is reaffirming today its guidance for adjusted net sales growth of
approximately 4% CER for both the fourth quarter of 2014 as well as the
full year.

Further, the Managing Board of QIAGEN N.V. decided today to launch an offer
by its subsidiary QIAGEN Finance (Luxemburg) S.A to repurchase all of
QIAGEN Finance (Luxemburg) S.A's outstanding convertible notes due 2024
(the "2024 Notes") as part of an initiative to optimize QIAGEN N.V.'s
balance sheet by reducing the related potential dilution of approximately
10.3 million shares. The cash tender offer is being made to holders of the
2024 Notes that are not persons located or residents in the United States.
Approximately $130 million of the aggregate principal amount of the
originally issued $150 million 1.5% 2024 Notes (ISIN XS0198529116) are
still estimated to be outstanding. The cash amount to repurchase all of the
outstanding 2024 Notes is estimated to be approximately $235 million.
Holders who tender their Notes will be paid from existing group cash
reserves.

The cash tender offer is being made to holders of the 2024 Notes that are
not persons located or residents in the United States. The offer is not
being made, directly or indirectly, in or into the United States, or by use
of the United States mails, or by any means or instrumentality (including,
without limitation, the post, facsimile transmission, telex and telephone,
e-mail or other form of electronic transmission) of interstate or foreign
commerce, or of any facility of a national securities exchange of the
United States. The offer cannot be accepted by any such use, means or
instrumentality or from within the United States. The tender offer is also
subject to restrictions in certain other jurisdictions.



QIAGEN N.V.
Spoorstraat 50 
5911 KJ Venlo
The Netherlands

ISIN: NL0000240000

[stock exchange, segment]


11.01.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      QIAGEN N.V.
              Spoorstraat 50
              5911 KJ Venlo
              Netherlands
Phone:        +31 77320 840-0
Fax:          +31 77320 840-9
E-mail:       qiagen@qiagen.com
Internet:     www.qiagen.com
ISIN:         NL0000240000
WKN:          901626
Indices:      TecDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
              in Berlin, Düsseldorf, Hamburg, München, Stuttgart;
              Terminbörse EUREX
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------